Tag Archives: physician

Rx Drug Task Force launches toolkit

11 Nov

INDIANAPOLIS – Attorney General Greg Zoeller joined the Prescription Drug Abuse Task Force today to launch a toolkit designed to help the state’s physicians navigate new rules for prescribing addictive pain medication. Zoeller made the announcement during the 4th Annual Prescription Drug Abuse Symposium in Indianapolis. Indiana’s Prescription Drug Abuse Task Force in partnership with the Indiana State Medical Association developed the toolkit titled, “First Do No Harm: The Indiana Healthcare Providers Guide to the Safe, Effective Management of Chronic Non-Terminal Pain.”This provider toolkit is based on expert opinion and recognized standards of care, with input from healthcare providers representing multiple specialties from all corners of the state,” Zoeller said. “It is our hope this new resource helps physicians understand and comply with the new prescribing rule recently adopted by the Medical Licensing Board. The new rule addresses the prescribing of pain medication for patients who have chronic, non-terminal pain in hopes of stemming the tides of addiction, doctor shopping and overprescribing.”

A recent study by Trust for America’s Health revealed the number of deaths caused by overdoses in Indiana has quadrupled since 1999This year, the Indiana General Assembly passed legislation which charged the Medical Licensing Board with developing new rules regarding prescribing controlled substances and strengthening the authority of the Attorney General’s office to inspect physician records in overprescribing cases. The two emergency rules stem in part from recommendations made by the task force.
Zoeller said the prescribing rule, adopted last week, aims to ensure patients are well informed about their prescriptions and physicians closely monitor patients to identify cases of misuse and abuse. Beginning Dec. 15, physicians will be required to monitor certain patient’s history via the state’s drug monitoring system called INSPECT which reveals what medications have been prescribed to a patient. Zoeller said this check can prevent someone from “doctor shopping” or obtaining multiple prescriptions for the same drug from different physicians
“The toolkit was developed by a diverse group of physicians, nurses, pharmacists, academics and public health professionals from across the state,” McMahan said. “Our goal is to educate Indiana healthcare providers on why these state-of-the art recommendations for safe prescribing are important and how to easily implement them in everyday practice. To help with that effort, the toolkit provides resources, templates and even talking points for those difficult-to-start conversations with patients.Zoeller said the growing number of cases involving licensed health professionals caught diverting drugs, overprescribing or fraudulently writing prescriptions is one reason he created the Prescription Drug Abuse Taskforce in 2012. Zoeller chairs the task force which is made up of state legislators, law enforcement, health officials, pharmacists, state and local agencies and education providers.

Earlier this year, Zoeller and the task force launched a statewide public awareness campaign and a website, http://www.BitterPill.IN.gov, to serve as a one-stop-shop for consumers looking for information about prescription drug abuse and where to find help.

Infant Acetamenophin Sold by Local Retailers Recalled

3 Nov

 

Walgreens, Kroger, Meijer and Babies R Us brands are among the listed batches of infant acetamenophin recalled today by manufacturer Perrigo.  The Kroger brand is sold locally at Food4Less stores.  While the product does not appear to be defective, the recall notice was issued because some packages may contain unmarked syringes.  The company warns that unmarked dosing syringes should not be used.  If you have a product that has dosage markings on the syringe, it is perfectly safe to use according to the release.  The complete list of brands and lot numbers is:

Label Batches
BABIES R US 3KK0606
CARE ONE 3HK0564
EQUALINE 3HK0672
EQUATE 3HK0672, 3JK0433, 3JK0594, 3JK0595, 3JK0653, 3JK0673, 3KK0815, 3KK0817
HARMON FACE VALUES 3JK0594
HEALTH MART 3HK0671
HEALTHY ACCENTS 3HK0671, 3KK0606
HEB 3KK0606
KROGER 3GK0645, 3GK0704, 3HK0671, 3JK0433, 3JK0595, 3JK0653, 3JK0433, 3JK0595, 3GK0645, 3GK0704, 3JK0595
LEADER DRUG 3JK0433, 3JK0594
MEIJER 3JK0594, 3JK0597
PUBLIX 3JK0595
RITE AID 3GK0704
TOPCARE 3KK0359, 3KK0494
UP & UP 3HK0672
WALGREEN 3GK0704, 3HK0564, 3HK0671, 3JK0433, 3JK0595, 3JK0610, 3KK0360

In a statement, the company said:

The Perrigo Company (NYSE: PRGO; TASE) announced today that it has initiated a voluntary, nationwide product recall to the retail level of 18 batches of its acetaminophen infant suspension liquid, 160 mg/5 mL, sold in 2 oz. and 4 oz. bottles with syringes in a box under the store brand products listed below above. The recall is being initiated because of the remote potential that a small number of packages might contain an oral dosing syringe without dose markings. The correct syringe should have a white or yellow plunger with specific dose markings for 1.25 mL, 2.5 mL, 3.75 mL, and 5 mL. If the product’s syringe has these dose markings, consumers can continue to use the product while following labeled use instructions.

Using an oral syringe without dose markings can result in inaccurate dosing, especially in infants who could mistakenly get too high a dose.

Commenting on this market action, Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “There are no issues or concerns with respect to the safety or efficacy of the product, only the potential that the oral dosing device in a relatively small number of packages could be unmarked. Out of an abundance of caution, we are taking this measure to maintain the highest possible product quality standards for our retail customers and consumers. While we cannot be certain that any of these unmarked dosing devices were released into our customers’ supply chains, taking this action is the right thing to do.” Perrigo has not received any reports or complaints related to this defect nor have they found any product with missing dose markings on re-examination of product on hand.

This OTC product is indicated for the relief of fever and minor aches and pains and can be used in infants, children and adults. These recalled products are sold by distributors nationwide and distributed through retail stores.

Perrigo is notifying its distributors and customers by verbal and e-mail communication today, followed by formal FedEx-delivered communication. It also is arranging for return of all recalled products. Distributors/retailers that have the acetaminophen infant suspension liquid that is being recalled should stop distribution and return product.

If the oral dosing device contained in the package has dose markings, no action is required, and the consumer can continue to use the product consistent with the label instructions. If the package contains an oral dosing device that does not have dose markings, the consumer should not use the product and should call Perrigo’s Consumer Affairs Department, toll free, 1-800-719-9260. Consumers should contact their physician or healthcare provider if they have any questions, or if they or their children experience any problem that could possibly be related to this drug product.

Adverse events that may be related to the use of this product may be reported to FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax:

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.